# Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children

> **NCT07318831** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 27 (estimated)

## Conditions studied

- Neuroblastoma (NB)
- Neuroblastoma in Children

## Interventions

- **DRUG:** Chidamide Combined with Dinutuximab Beta, Irinotecan, and Temozolomide

## Key facts

- **NCT ID:** NCT07318831
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07318831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07318831, "Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07318831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*